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Abstract
Immunotherapy with high-dose interleukin-2 (HDIL-2) is an effective treatment for patients with metastatic melanoma and
renal cell carcinoma. However, it is accompanied by severe toxicity involving endothelial cell injury and induction of vascular
leak syndrome (VLS). In this study, we found that resveratrol, a plant polyphenol with anti-inflammatory and anti-cancer
properties, was able to prevent the endothelial cell injury and inhibit the development of VLS while improving the efficacy
of HDIL-2 therapy in the killing of metastasized melanoma. Specifically, C57BL/6 mice were injected with B16F10 cells
followed by resveratrol by gavage the next day and continued treatment with resveratrol once a day. On day 9, mice
received HDIL-2. On day 12, mice were evaluated for VLS and tumor metastasis. We found that resveratrol significantly
inhibited the development of VLS in lung and liver by protecting endothelial cell integrity and preventing endothelial cells
from undergoing apoptosis. The metastasis and growth of the tumor in lung were significantly inhibited by HDIL-2 and
HDIL-2 + resveratrol treatment. Notably, HDIL-2 + resveratrol co-treatment was more effective in inhibiting tumor metastasis
and growth than HDIL-2 treatment alone. We also analyzed the immune status of Gr-1
+CD11b
+ myeloid-derived suppressor
cells (MDSC) and FoxP3
+CD4
+ regulatory T cells (Treg). We found that resveratrol induced expansion and suppressive
function of MDSC which inhibited the development of VLS after adoptive transfer. However, resveratrol suppressed the
HDIL-2-induced expansion of Treg cells. We also found that resveratrol enhanced the susceptibility of melanoma to the
cytotoxicity of IL-2-activated killer cells, and induced the expression of the tumor suppressor gene FoxO1. Our results
suggested the potential use of resveratrol in HDIL-2 treatment against melanoma. We also demonstrated, for the first time,
that MDSC is the dominant suppressor cell than regulatory T cell in the development of VLS.
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Introduction
High-dose interleukin-2 (HDIL-2) therapy which produces
overall response rates of 15% to 23% remains an effective and
long-lasting treatment for metastatic renal cell carcinoma and
melanoma [1,2]. However, it is associated with significant systemic
toxicity, mainly, vascular leak syndrome (VLS), characterized by
increased vascular permeability and decreased microcirculatory
perfusion that causes extensive fluid retention in multiple organs
and can lead to pulmonary and cardiovascular failure [3,4,5]
Although it is dose-dependent and reversible with therapy
discontinuation, there is no specific and effective treatment
regimen. The endothelial cell damage is the major feature of the
vascular pathology. Direct effects of IL-2 on endothelial cells [6,7],
or through induction of inflammatory cytokines such as TNF-a,
IL-1 and IFN-c [3], have been previously reported. Otherwise, the
cytotoxic effects by lymphokine-activated killer cells (LAK) are the
main cause of vascular injury [8,9,10,11].
Immunoregulation associated with the development of IL-2-
induced VLS is not known. Our lab has reported that T regulatory
cells (Treg) were amplified in vivo by IL-2 treatment; they suppress
the cytolytic killing of endothelial cells by LAK cells in the in vitro
experiments, thereby suggesting that Treg play a role in the
negative regulation on the development of HDIL-2-induced VLS
[12]. Lately, functional importance of myeloid-derived suppressor
cells (MDSC) in immune responses has been appreciated. MDSC
are a heterogeneous population of cells consisting of myeloid
progenitor cells and immature myeloid cells. They are character-
ized by the co-expression of the myeloid lineage differentiation
molecule Gr1 and CD11b. These cells markedly expand
systemically in pathological conditions, such as cancer, various
infectious diseases and some autoimmune diseases [13,14].
Accumulating evidence demonstrates that their suppressive
functionality contributes to the negative regulation of immune
responses including adaptive and innate immunity, such as
suppressing various T-cell functions, and NK and CTL cytotox-
icity [13,14,15,16,17,18]. However, the role of MDSC in HDIL-2-
induced inflammation and the development of VLS have not been
elucidated.
Resveratrol, a naturally occurring polyphenol found in grapes
and red wine, is widely used in animal models and possesses
broad-spectrum of beneficial health effects including anti-infective,
anti-inflammatory, and antioxidant properties. These interesting
properties confer the cardiovascular protective capacity and ability
to protect endothelial function on resveratrol [19,20]. In cancer
patients, resveratrol exhibits anticancer properties, such as
suppression of tumor cell proliferation, induction of tumor cell
apoptosis, increase in chemosensitization of tumor cells, and exerts
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resveratrol suppresses tumor growth by inducing apoptosis in
tumor cells through aryl hydrocarbon receptor (AhR) and by
reciprocal regulation of SIRT1 and NF-kB signaling [23]. For
melanoma, experiments showed that resveratrol can enhance
chemical cytotoxicity to the tumor, and suppress tumor growth by
inducing cell-cycle interruption and apoptosis [24,25]. Neverthe-
less, effects of resveratrol on the development of VLS in HDIL-2
therapy against melanoma have not been studied.
In this report, we studied the role of resveratrol in the
development of VLS in B16F10 melanoma-bearing mice and
revealed its role in protection of the endothelium and suppression
of metastasis. We also discovered a novel functional characteristic
of resveratrol in induction of suppressive activity of MDSC and
expression of FoxO1 transcripts in context of suppressing the
development of VLS and the growth and metastasis of B16F10
melanoma.
Materials and Methods
Ethics statement, mice and recombinant IL-2
Female C57BL/6 (6–8 wk of age) mice were purchased from
NIH. All animals were housed in University of South Carolina
Animal Facility. All animal procedures were performed according
to NIH guidelines under protocols approved by the Institutional
Animal Care and Use Committee of the University of South
Carolina. Recombinant IL-2 was provided by the NCI Biological
Resources Branch (Rockville, MD). All antibodies were purchased
from Biolegend.
3H-thymidine and
51NaCr04 were purchased
from MP biomedical. Resveratrol was purchased from Sigma or
Supelco (Bellefonte, PA).
Induction and quantification of VLS
VLS was induced by IL-2 according to the established method
from our lab [12,26,27,28]. On day 0, groups of 4–5 mice were
injected intraperitoneally with 75,000 units of IL-2 or PBS as
a control, 3 times a day for 3 consecutive days. On day 4, the mice
received one injection and 2 h later were injected intravenously
with 0.1 ml of 1% Evan’s blue in PBS. After 2 h, the mice were
exsanguinated under anesthesia, and the hearts were perfused with
heparin-PBS until lungs and livers were blanched. The lungs and
livers were harvested and placed in formamide at 37uC overnight.
The Evan’s blue in the organs was quantified by measuring the
absorbance of the supernatants at 650 nm with a spectrophotom-
eter. For administration of resveratrol, mice were administered
resveratrol (100 mg/kg body weight) on day -1 by gavage, and
thereafter once a day 1 h before the first IL-2 injection during
day 0 to day 4. The VLS seen in IL-2-treated mice was expressed
as percentage of increase in extravasation of Evan’s blue when
compared with that of the PBS-treated controls and was calculated
as: [(OD650 in the organs of IL-2-treated mice)-OD650 in the
organs of PBS-treated controls)]/(OD650 in the organs of PBS-
treated controls) 6100. Each mouse was individually analyzed for
vascular leak, and data from 4–5 mice were expressed as mean
6SEM.
Tumor cell implantation, HDIL-2 and resveratrol
treatment
Mice were injected with 5610
5 B16F10 cells intravenously or
implanted with 2610
5 B16F10 cells subcutaneously on day 0. The
B16F10 melanoma cell line was purchased from American Type
Culture Collection (Manassas, VA) and maintained as recom-
mended by the supplier [26]. We started to treat mice with
resveratrol on day 1 and induce VLS with HDIL-2 on day 9 as
described above. On day 12, mice were sacrificed to evaluate VLS
and tumor metastasis in lungs. Black nodules were counted under
a dissecting microscope on the surface of the lung specimens.
These nodules exhibited characteristic histological features of
metastatic melanomas (data not shown). The area of each nodule
was measured with software Image Pro. The area of each nodule
was normalized to the whole area of the same lobe and multiplied
by 1000. The average area of the normalized measurement was
present. For the primary tumors in the skin, they were resected
and weighed, and then used for the total RNA extraction.
Flow cytometry studies of MDSC and Treg
For flow cytometry analysis, splenocytes were prepared. Red
blood cells were lysed using red blood cell lysing buffer (Sigma).
Lung and liver infiltrating inflammatory cells were isolated using
Percoll gradient centrifugation (detailed below). Cells were re-
suspended in staining buffer (PBS containing 2 mM EDTA and
2% fetal bovine serum) and pre-incubated for 10 min at room
temperature with purified anti-CD16/32 antibody to block non-
specific binding of antibodies to Fcc receptors. For analysis of
MDSC, cells were then incubated with FITC-conjugated anti-
mouse CD11b and PE-conjugated anti-mouse Gr-1 mAbs in the
staining buffer for 30 min at 4uC. For analysis of Treg, cells were
incubated with FITC-conjugated anti-mouse CD4 mAb in the
staining for 30 min at 4uC, then fixed and permeabilized with
FoxP3 fix/perm buffer at room temperature in the dark for
20 min. The cells were washed once in FoxP3 perm buffer and
continued to stay in FoxP3 perm buffer at room temperature for
15 min. Cells were spun down and re-suspended in 100 ml fresh
FoxP3 perm buffer. Cells were then incubated with PE-conjugated
anti-mouse FoxP3 mAb at room temperature in the dark for
30 min. After incubation with the mAbs, cells were washed twice
in the staining buffer and re-suspended in the staining buffer. The
staining was analyzed with a CXP500 flow cytometer with post-
acquisition data analysis using CXP500 software (Beckman
Coulter). All antibodies were purchased from Biolegend.
Figure 1. Decreased VLS in resveratrol-treated non-tumor
mice. Non-tumor bearing mice were given HDIL-2 and/or resveratrol.
The vascular leak in the lungs and liver as well as TNF-a in the serum
were measured. A. VLS in lung. B. VLS in liver. C. The TNF-a level in the
serum was measured by sandwich ELISA.
doi:10.1371/journal.pone.0035650.g001
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MDSC were sorted by two steps. First, MDSC cells were
enriched from splenocytes of VLS mice by depletion of other cells
(CD4+, CD8+, CD90.2+, B220+, NK1.1+, F4/80+, CD11C+,
CD117+) with magnetic beads, and then, CD11b
+Gr-1
+ double
positive cells were sorted by a flow cytometer. Briefly, splenocytes
at a density of 1610
8 cells/ml in the staining buffer were pre-
incubated for 10 min with purified anti-CD16/32 antibody to
block non-specific binding of antibodies to Fcc receptors, and then
incubated with biotin-conjugated anti-mouse CD4, CD8, CD90.2,
B220, NK1.1, F4/80, CD11c, and CD117 mAbs for 15 min at
room temperature. Cells were washed once with and re-suspended
in the staining buffer at the same cell density. Cells were then
incubated with EasySep biotin cocktail (Stemcell) at room
temperature for 15 min followed by incubation with EasySep
magnetic particles (Stemcell) at room temperature for 10 min.
Non-magnetic binding cells were collected, and further incubated
with FITC-conjugated anti-mouse CD11b and PE-conjugated
anti-mouse Gr-1 mAbs for 30 min at 4uC. Cells were washed twice
with and re-suspended in the staining buffer. CD11b and Gr-1
double positive cells were then sorted by a FACSAria sorter. The
purity was .98%. For adoptive transfer, 1610
6 cells were
transferred per recipient mouse intravenously.
Generation of LAK cells and
51Cr release assay
LAK cells were prepared as previously described [12,26,27,28].
For generation of LAK cells in vitro, splenocytes from naı ¨ve mice
were cultured for 48 h with 1000 units/ml IL-2 in RPMI
containing 10% fetal bovine serum, 10 mM HEPES, 1 mM
sodium pyruvate, 2 mM L-glutamine, 0.1 mM non-essential
amino acid, 100 units/ml penicillin, 100 mg streptomycin, and
50 mM b-mercaptoethanol. Viable cells were purified by density
gradient centrifugation using NycoPrep (Cedarlane, Burlington,
NC). Such cells will be referred to as LAK cells. For generation of
LAK cells in vivo, mice were treated with IL-2 as described above.
On day 4, splenocytes were prepared and viable cells were
Figure 2. Decreased VLS and increased tumor regression in resveratrol-treated melanoma-bearing mice. C57BL/6 mice were injected
i.v. with B16F10 melanoma cells (5610
5 cells/mouse) and adminsitered resveratrol as described in Fig. 1. On day 9, mice were treated with IL-2 as in
Fig. 1. The mice were sacrificed for evaluation of VLS on day 12. The numbers of black metastatic nodules on the lung surfaces were counted under
a microdissecting microscope. The area of each nodule was measured with software Image Pro. The values are shown as mean 6SEM. A. VLS in lung.
B. VLS in liver. C. Enumeration of lung metastatic nodules. D. Area measurement of lung metastatic nodules. E. Histopathology of lung metastasis on
the surface of one lobe.
doi:10.1371/journal.pone.0035650.g002
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of LAK cells was tested against B16F10 tumor or TME endothelial
cells using 4 h
51Cr-release assay. Briefly, 1610
6 target cells were
labeled with 100 mCi of
51NaCrO4 (MP Biomedicals) at 37uC for
1 h, washed three times in RPMI 1640 culture medium, and
adjusted to 1610
5 cells/ml. In brief, 1610
4 target cells were
plated into 96-well U-bottom plates with varying numbers of LAK
cells depending on the respective E:T cell ratios. In these
experiments, the LAK cells were defined as the effector cells (E)
that mediate lysis of the
51NaCrO4-labeled endothelial cells or
tumor cells, which were defined as the target cells (T). In some
groups, target cells were incubated with resveratrol (25 mM) for
2 h at 37uC before they were added into the plates. For analysis of
MDSC suppression, LAK cells were incubated with MDSC for
2 h before adding to the plates. Spontaneous release of
51NaCrO4
was determined by culturing the target cells alone, and the
maximum release of
51NaCrO4 was determined by incubating the
target cells with 1% SDS. The supernatants were harvested after
4 h culture, and the radioactivity was measured using a Microbeta
counter (PerkinElmer). Percentage of killing efficiency of LAK cells
was calculated as percent cytotoxicity = [(sample cpm 2
spontaneous release cpm)/(maximum release cpm 2 spontaneous
release cpm)] 6100. The data were represented as mean 6SEM.
Each group had four wells.
Isolation of T cells and infiltrating inflammatory cells
To isolate T cells from spleen, splenocytes were stained with
anti-CD3 Abs, followed by magnetic beads isolation. For isolation
of infiltrating mononuclear cells (MNCs) from lung or liver, mice
were perfused. Lung or liver was minced and passed through
100 mm filter. Single-cell suspensions were subject to Percoll
gradient (70%/30%) centrifugation.
TUNEL assay of cell apoptosis
Cell apoptosis was evaluated with conventional TUNEL assay
using DeadEnd Colorimetric TUNEL System from Promega by
following the manufacturer’s instructions. Numbers of TUNEL-
Figure 3. Resveratrol protects endothelial integrity. The ultrastructural studies showed resveratrol protects endothelial cells. Panels 1 and 2
show PBS- or resveratrol-treated mice, respectively. The endothelial cell (En) lining the blood vessel is firmly anchored to the basal lamina (BL) with
good integrity, thereby showing normal morphology. The cell has an intact nucleus (Nu) and is closely opposed to the intact basal lamina. Three RBCs
lie within the blood vessel lumen. Panel 3 shows IL-2-treated mice with significant damage to the endothelial cells. Cell membrane is folding (F) and
discontinuous (D). Vacuolation (V) is found under the folded cell membrane and within the cytoplasm. In addition, some endothelial cells have lost
the normal morphology, with only extended cell membrane remnants remaining. Cellular debris from former endothelial cells can be found in the
blood vessel lumen. An RBC fills the lumen. Panel 4 shows IL-2+resveratrol-treated mice with normal endothelial cell morphology. The cell membrane
and cytoplasmic contents are well defined and closely adhere to the basal lamina. The intact nucleus is closely opposed to the intact basal lamina
Three RBC fill the lumen. Original magnification, 620,000.
doi:10.1371/journal.pone.0035650.g003
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slide and the data were expressed as mean 6SE of apoptotic cells
per vessel.
Histological Analysis of cell infiltration and measurement
of serum TNF-a
The lungs and livers were fixed in 10% formalin solution. The
organs were embedded in paraffin, sectioned, and stained with
hematoxylin and eosin. Perivascular infiltration was scaled by
counting the number of lymphocytes infiltrating around the vessel
and averaging the minimum and maximum range for each group.
Five samples per mouse were analyzed, and a minimum of four
mice were included. Sera were prepared for detection of TNF-a by
sandwich ELISA using TNF-a ELISA kit (Biolegend).
Electron microscopic studies of vascular injury
Tissue samples were fixed in 5% glutaldehyde/4.4% formalde-
hyde/2.75% picric acid in 0.05 M sodium cacodylate buffer,
pH 7.4, washed in a sodium cacodylate buffer, postfixed in
osmium tetroxide, embedded in Polybed 812 resin (Polysciences,
Warrington, PA) and studied with an electron microscope.
[
3H]-thymidine incorporation assay
LAK cells generated from IL-2 treated mice were cultured in
complete RPMI 1640 medium in a 96-well round bottom plate.
[
3H]-thymidine (1 mCi/well) was added to the culture. In some
groups, LAK cells were incubated with MDSC at 10:1 ratio
(LAK:MDSC) for 2 h before adding [
3H]-thymidine. At 16 h,
cultures were harvested using a cell harvester and the radioactivity
incorporated in the cells was measured in a beta counter
(Microbeta counter, Perkin Elmer).
Quantitative real-time PCR (QPCR)
Total RNAs were prepared and reversely transcribed to cDNA
using miRNeasy Mini Kit and miScript Reverse Transcription Kit
(Qiagen). FoxO1, arginase 1 (Arg1), aryl hydrocarbon receptor
(AhR), and 18S RNA (18S) were amplified using miScript SYBR
Green PCR kit (Qiagen) in a StepOnePlus PCR amplifier (ABI).
The relative gene expression level was normalized to the
endogenous control 18S. The primer sequences were listed below.
FoxO1 F: TGT TAG GCC CAC CAC ACG AGT TTA; FoxO1
R: GGT GAA AGC AAA GGG CTC CAA TGT; Arg1 F: ACG
GCA GTG GCT TTA ATT GGC; Arg1 R: TCT GTC TGC
TTT GCT GTG ATG CC; NOS2 F: TGC CAC CAA CAA
TGG CAA CAT C; AhR R: TTG AAG TCA ACC TCA CCA
GCA GC; 18S F: AAA GGA ATT GAC GGA AGG GCA CC;
18S R: AAC TAA GAA CGG CCA TGC ACC AC.
Statistical analysis
Data were presented as mean 6SEM and analyzed for
significance using non-paired Student’s t-test. In case of multiple
testing, One-way ANOVA test followed by Newman-Keuls
Figure 4. Histological studies of the lung and the liver for inflammatory cell infiltration. Lungs and livers from VLS mice were harvested
and preserved in 10% formalin solution. Sections were stained with hematoxylin and eosin. The level of perivascular infiltration was determined by
counting the number of cells infiltrating around a venule. The data depicts the mean 6SEM of sections from four individual mice. A. The level of
perivascular infiltration in lungs. B. The level of perivascular infiltration in livers. C. Statistic analysis of the infiltration depicts p.0.05 between IL-2 and
IL-2+Resveratrol groups. Original magnification, 6200.
doi:10.1371/journal.pone.0035650.g004
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software. Comparisons were considered significant at p#0.05.
Results
Resveratrol prevents VLS while maintaining the
effectiveness of HDIL-2 treatment
HDIL-2 has been shown to have significant efficacy against
advanced stages of melanoma. However, HDIL-2 treatment is
accompanied by significant toxicity including VLS which limits its
therapeutic efficacy [1,2,3,4,5]. In the current study, we first
evaluated whether resveratrol plays any role in the prevention of
HDIL-2-induced VLS. For this purpose, we induced VLS in
normal mice with HDIL-2. Resveratrol was given to mice one day
before HDIL-2 treatment and once a day during the treatment
until the day of sacrifice of mice. Four sets of experiments were
established: IL-2 treatment (IL), resveratrol treatment (Res), IL-2 +
resveratrol co-treatment (IL+R), and PBS treatment (PBS). The
results showed that the vascular leak was dramatically suppressed
by resveratrol treatment. Serum levels of TNF-a were also
significantly decreased in resveratrol treatment group (Fig. 1).
These results demonstrated that resveratrol can prevent IL-2-
induced VLS.
Next, we tested whether resveratrol exerts a similar effect in
melanoma-bearing mice. To this end, C57BL/6 mice were
injected i.v. with B16F10 melanoma cells (5610
5 cells/mouse).
On day 9, mice were treated with IL-2 or resveratrol as described
above. The mice were euthanized for evaluation of VLS on
day 12. Our results showed that resveratrol significantly inhibited
VLS in tumor-bearing mice both in the lungs and liver to a similar
extent when compared to that seen in the non-tumor-bearing mice
(Fig. 2A and 2B). The metastasis and tumor growth in lungs (seen
as black nodules) were significantly inhibited by IL-2 or
IL2+resveratrol co-treatment. Moreover, IL2+resveratrol co-
treatment was more effective in inhibiting tumor metastasis than
IL-2 treatment alone (Fig. 2C–2E). These results indicated that
Figure 5. Resveratrol protects endothelial cells from apoptosis. Lungs from PBS, resveratrol, IL-2 or IL-2+resveratrol-treated mice were
examined for apoptosis with TUNEL assay as described in Materials and Methods. Apoptotic cells are depicted by brown stained nuclei (arrow). The
histogram shows the quantification of apoptotic cells. Original magnification, 6400.
doi:10.1371/journal.pone.0035650.g005
Resveratrol in IL-2 Therapy against Melanoma
PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e35650resveratrol can ameliorate IL-2 toxicity while promoting the
effectiveness of IL-2 in metastatic melanoma therapy.
Resveratrol does not affect infiltration of inflammatory
cells but protects endothelial cell integrity and prevents
the cells from undergoing apoptosis
We previously found that HDIL-2-therapy caused endothelial
cell (EC) damage by activating LAK cells [26,28,29]. Therefore,
we investigated if resveratrol-mediated suppression of VLS
resulted from its protective effect on ECs by pursuing ultrastruc-
tural studies of the lungs. As shown in Fig. 3, ECs from PBS or
resveratrol group showed normal morphological features. In
contrast, ECs from IL-2-treatment group revealed extensive
damage, including cell membrane folding or break and vacuola-
tion of cytoplasmic particles. Some of the endothelial cells were
severely damaged, with only extended cell membrane remnants
remaining. Cellular debris from ECs was found in the blood
capillary lumen [26]. Interestingly, IL2+resveratrol treatment
exhibited morphologically normal ECs and the basal lamina,
whereas we only found minor damage in few endothelial cells.
We wondered whether suppression of IL-2 induced VLS by
resveratrol resulted from inability of inflammatory cells to infiltrate
into the organs. Therefore, the inflammatory cell extravasation
was examined under microscope. The results showed that the IL-2
treatment induced significant perivascular infiltration both in lungs
and liver. Notably, IL-2 + resveratrol co-treatment also exhibited
similar levels of perivascular infiltration as the IL-2 treatment. The
degree of infiltration was also measured by counting the layers of
cell infiltration around each vessel and averaging the numbers for
each group (Fig. 4). These data suggested that the suppression of
VLS seen in IL-2 + resveratrol treated-mice was not due to the
inability of infiltration of inflammatory cells.
We previously reported that apoptosis could be one of the
mechanisms of EC damage [26]. Hence, we applied TUNEL
assay to examine apoptosis in lung sections. Our results showed
that IL-2-treated mice exhibited a large number of ECs that had
undergone apoptosis, which was determined by TUNEL-positive
staining. In contrast, IL-2+resveratrol treated-mice did not show
TUNEL-positive cells (Fig. 5). These data suggested that
Figure 6. Resveratrol inhibits IL-2-induced expansion of Treg. Splenocytes and infiltrating cells were stained with FITC-conjugated anti-CD4
mAb, fixed and permeabilized and incubated with PE-conjugated anti-FoxP3 mAb as described in Materials and Methods. The stained cells were
analyzed by flow cytometry. The representative dot plots from spleen (A), lung (B), and liver (C) and the statistical analysis of the percentage mean
6SEM of Treg (D) are shown.
doi:10.1371/journal.pone.0035650.g006
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tural damage and apoptosis.
Resveratrol induced expansion and suppressive
functionality of myeloid-derived suppressor cells (MDSC)
To explore the underneath mechanisms that contribute to the
suppressive function of resveratrol on VLS, we studied the
contribution of the suppressor cells in the inhibition of VLS by
resveratrol. To this end, we focused on studies of Treg and
MDSC. Our previous study showed that IL-2 treatment could
induce expansion of CD4
+FoxP3
+ Treg; these Treg can suppress
the cytolytic killing of ECs by LAK cells in vitro [12]. In the current
study, we measured the percentage of Treg in spleen, lung and
liver. On day 12, the splenocytes and the infiltrating-mononuclear
cells from lung and liver were prepared for staining of CD4 and
FoxP3. The results showed that IL-2 caused an expansion of Treg
in spleen, lung and liver. However, resveratrol treatment did not
induce their expansion; instead, it inhibited Treg expansion to
some extent (Fig. 6). Simultaneously, we stained cells for Gr-1 and
CD11b expression. The results showed that either resveratrol or
IL-2 could induce the expansion of MDSC. Moreover, combina-
tion of IL-2+resveratrol caused a further induction of MDSC
(Fig. 7). These results suggested the possibility that MDSC rather
than Treg probably contributed to the suppression of VLS in
resveratrol treatment.
To address this further, we examined the suppressive ability of
MDSC on LAK cytotoxicity and proliferation. To this end, LAK
cells from IL-2-treated mice were isolated, and then incubated
with MDSC at 10:1 ratio (LAK: MDSC) for 2 h at 37uC. For the
cytotoxicity assay, the mixture of the culture was added to
51Cr-
labeled EC target (TME cell line) at 50:1 ratio (E:T) followed by
4h
51Cr-release assay. For the proliferation assay, the mixture of
the culture was supplemented with
3H-thymidine and continued
culture for 16 h and then the
3H-thymidine incorporation was
measured. To our surprise, the results showed that MDSC from
IL-2+resveratrol group (named as R-MDSC) significantly inhib-
ited LAK cytotoxicity and proliferation; however, MDSC from IL-
2 group (named as IL-MDSC) did not show any suppressive effects
on either LAK cytotoxicity or proliferation (Fig. 8A & 8B).
Figure 7. Expansion of MDSC by IL-2 and/or resveratrol treatment. Splenocytes and the infiltrating cells were stained with FITC-conjugated
anti-CD11b and PE-conjugated anti-Gr-1 mAbs. The stained cells were analyzed by flow cytometry. The representative dot plots from spleen (A), lung
(B), and liver (C) and the statistical analysis of the percentage mean 6SEM of MDSC (D) were shown.
doi:10.1371/journal.pone.0035650.g007
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role in the development of VLS in vivo, we transferred these
MDSCs intravenously into naı ¨ve mice and induced VLS in the
recipient mice on the same day of the cell transfer. The results
showed that R-MDSC caused marked inhibition of VLS; again,
IL-MDSC did not inhibit VLS at all (Fig. 8C). Correspondently,
we found that resveratrol induced the expression of Arg1 in
MDSC but IL-2 did not. Interestingly, IL-2 and resveratrol co-
treatment induced the most expression of Arg1 (Fig. 8D). This
could be because resveratrol is more effective in activated cells
than unactivated cells [30]. We also found that R-MDSC and IL-
MDSC have different expression level of AhR, which is the main
receptor for resveratrol-derived signaling [23]. We found that
resveratrol increased the expression of AhR in MDSC but IL-2 did
not. Similar to the expression of Arg 1, IL-2 and resveratrol co-
treatment induced the most expression of AhR (Fig. 8E). All
together, our results indicated that resveratrol can elicit or
enhance the suppressive functionality of MDSC that could
contribute to the suppression of VLS.
Resveratrol induced expression of FoxO1 in tumor cells
Thus far, we demonstrated that resveratrol can ameliorate IL-2
toxicity while promoting the effectiveness of IL-2 in metastatic
melanoma therapy. We showed that resveratrol-treated MDSC
could contribute to the suppression of the cytolytic activity of LAK
cells on ECs. However, MDSC are generally recognized for their
role in helping evasion of tumor by suppressing the host immunity
in situ of the tumor. Our results raised the possibility that
resveratrol possesses the specific characteristic that can overcome
the suppressive effect of MDSC to the tumor. To explore the
possible mechanisms, we studied whether resveratrol played a role
in the expression of the tumor suppressor genes by analysis of
FoxO1 gene expression. To this end, we resected the primary
melanoma in the skin and examined the transcripts of FoxO1 by
QPCR. The results showed that either resveratrol or IL-2
treatment can induce the expression of FoxO1 in the tumor in
vivo. IL-2 and resveratrol co-treatment induced the highest
expression of FoxO1 (Fig. 9A). Correspondently, the growth of
the tumor was significantly inhibited by the treatment which was
demonstrated by the decreased tumor weight while IL-2 and
resveratrol co-treatment can exert the maximal inhibitory effects
on the tumor growth (Fig. 9B).
We also cultured B16F10 cells with IL-2 and/or different dose
of resveratrol. We found that resveratrol could induce the
expression of FoxO1 in a dose-dependant manner. However,
IL-2 alone did not induce the expression of FoxO1. This
concentration of IL-2 is effective in LAK cell development [26].
With IL-2 and resveratrol co-treatment, the expression levels of
FoxO1 were not different from the resveratrol treatment alone
(Fig. 9C), which suggest that IL-2 does not directly affect the
expression of FoxO1 in B16F10 tumor cells. However, in the in
vivo experiment, HDIL-2 administration did induce the expression
of FoxO1 in the primary tumors (Fig. 9A). These results indicate
that the release of other factors from the HDIL-2-induced
inflammation could trigger the expression of FoxO1 in the tumor,
and such factors work together with resveratrol co-treatment to
further enhance the expression of FoxO1.
Resveratrol makes melanoma more susceptible to the
cytotoxicity of LAK cells by increasing the sensitivity of
the tumor cells to the cytotoxicity
It has been shown that resveratrol can suppress melanoma
growth by inducing the cell-cycle interruption and apoptosis in the
tumor cells; resveratrol also can enhance the chemical cytotoxicity
to the tumor by the chemotherapeutic agents [24,25]. In this
study, we studied whether resveratrol could affect the LAK
cytotoxicity to the tumor. To this end, LAK cells were used as the
effectors and generated in vitro from splenocytes of normal mice as
described in the Materials and Methods. B16F10 cells were used as
the targets. We pre-incubated the targets with resveratrol at
25 mM for 2 h at 37uC before the 4 h cytotoxicity assay. The
results showed that the pre-treatment of resveratrol significantly
increased the number of the killed targets by LAK cells (Fig. 9D).
The above results suggested that resveratrol can directly induce
the expression of the tumor suppressor gene FoxO1, thereby
leading to the suppression of the tumor growth and cell death by
triggering autophagy [31,32]. IL-2 can facilitate such effects by the
unknown factors from the HDIL-2-induced inflammation. Mean-
while, resveratrol directly enhances the susceptibility of B16F10
tumor cells to the LAK cytotoxicity. Together, these mechanisms
Figure 8. Analysis of the functional characteristics of MDSC.
Panel A: MDSC were isolated from IL-2 and IL-2+resveratrol treatment
(labeled as IL-MDSC and R-MDSC respectively). LAK cells from IL-2
treated mice were isolated and incubated with MDSC for 2 h, and then
used as effectors in the cytotoxicity assay against EC cell targets. Panel
B:
3H-thymidine incorporation assay to measure the proliferation of the
LAK cells in the panel A. Panel C: 1610
6 MDSC were intravenously
transferred to naive mice. VLS was then induced in the recipient mice.
Panel D & E: Total RNA was extracted from the MDSC with the
respective treatment. Expression of Arg1 (D) and AhR (E) were detected
by QPCR. The relative expression was normalized to the endogenous
18S.
doi:10.1371/journal.pone.0035650.g008
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immunity of the host that eventually leads to the tumor regression.
Discussion
Our results support a potential use of resveratrol in HDIL-2
treatment against melanoma and revealed some mechanisms. The
resveratrol treatment effectively inhibited the development of VLS
that is the most severe side-effect from HDIL-2 therapy.
Meanwhile, the co-treatment with resveratrol and HDIL-2
promoted the efficacy of the tumor therapy arisen from either
resveratrol or HDIL-2 treatment. Resveratrol played a differential
role in the protection of EC injury and killing of the tumor. On the
one hand, resveratrol prevented ECs from the ultrastructural
damage and apoptosis; on the other hand, it increased the tumor
killing by enhancing the susceptibility of the tumor to the
cytotoxicity killer cells.
To understand how resveratrol played the suppressive role in
the development of VLS, we focused on the study of Treg and
MDSC, the two main populations of the immune suppressors. We
found that resveratrol induced the expansion of MDSCs that can
suppress the cytolytic killing of ECs and the development of VLS
while the number of Treg decreased at the same time. Previous
studies from our lab and the others also showed that resveratrol
inhibited the production of TGF-b and the expansion of Treg in
the tumor-bearing mice while it induced the expansion of MDSCs
that suppressed the development of chronic colits [33,34]. These
results demonstrate that MDSC is the predominant suppressor
cells than Treg in the development of VLS. It could be true since
MDSCs are the dominant suppressor cells that induce the tumor
escape than Treg [35]. This conclusion could be corroborated by
the fact that HDIL-2 treatment can induce the expansion of Tregs
but they are not able to prevent the development of VLS [12].
There are conflicting reports on whether MDSC are involved in
the induction of Treg [13]. It was also reported that both Treg and
MDSC could expand in the tumor-bearing mice, and that the
expansion of the two populations were not related [36]. Here, we
showed that IL-2 treatment induced both MDSC and Treg
expansion. However, resveratrol treatment only induced MDSC
expansion while it inhibited Treg expansion. Therefore, our
current study demonstrates a differential role of resveratrol on
Treg and MDSC.
The expansion of MDSC in HDIL-2 immunotherapy was
found in patients with renal cell carcinoma (RCC) therapy. In
these patients, an increased secretion of Arg1 in the patients blood
was also detected [37,38]. However, the role of MDSC in the
development of HDIL-2-induced VLS and their functionality has
not been studied before. In the current report, we found that
HDIL-2-induced MDSCs from spleen were not suppressive. This
is not surprising considering that MDSCs from spleen of naı ¨ve
mice or tumor-bearing mice do not possess the suppressive
Figure 9. Resveratrol enhances the expression of FoxO1 and the cytolytic susceptibility of melanoma. Panel A and B: C57BL/6 mice
were implanted s.c. with B16F10 melanoma cells (2610
5 cells/mouse) and orally administered with resveratrol. On day 9, mice were treated with IL-2
as described in Fig. 1. The mice were sacrificed for evaluation of VLS on day 12. The primary tumors in the skin were resected and weighed. Total RNA
was extracted. Expression of FoxO1 was detected by QPCR (A). The relative expression was normalized to the endogenous 18S. The mean 6SEM of
weight is shown (B). Panel C: B16F10 cells were cultured with vehicle (Veh), IL-2 (IL) (1000 units/ml), or resveratrol at the indicated dose for 24 h. Total
RNA was extracted. Expression of FoxO1 was detected by QPCR. Panel D: LAK cells were generated by culturing splenocytes from naı ¨ve mice with IL-2
(1000 units/ml) for 48 h. B16F10 cells were incubated with resveratrol (25 mM) for 2 h and labeled with
51Cr. The labeled B16F10 cells were then
added to the LAK cells. After 4 h, the release of
51Cr was measured and percent cytotoxicity was calculated. Statistical analysis was performed at each
effector to target ratio and showed p,0.001.
doi:10.1371/journal.pone.0035650.g009
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derived factors, which is corroborated by the fact that MDSC from
tumor tissue rather than spleen possess the suppressive character-
istics. In these studies, the authors claimed that the regaining of
suppressive function was because these MDSC differentiated into
suppressive macrophages (F4/80
+) [35,39,40]. In our report,
resveratrol administration recovered their suppressive functional-
ities including the expression of Arg1, the suppression of the
proliferation and cytotoxicity of LAK cells, as well as suppression
of the development of VLS after the adoptive transfer (Fig. 8A–
8D).
Whether resveratrol can induce the differentiation of the
suppressive macrophages or how resveratrol recoveres the
suppressive function of MDSC is not clear. We examined the
interaction between resveratrol and MDSC. AhR functions as one
the main receptors for resveratrol [23]. Our results demonstrated
that resveratrol could induce the expression of AhR in the MDSC
while IL-2 could not. Interestingly, IL-2 and resveratrol co-
treatment induced the most expression of AhR (Fig. 8E). This
could be because resveratrol is more effective in activated cells
than unactivated cells [30]. We noted that the expression of AhR
was positively related to the expression level of Arg1 and
suppression functionality of MDSC. IL-MDSC showed the lowest
level of AhR whereas R-MDSC showed the highest level of AhR.
We assume that the signals from AhR may be critical for MDSCs
to recover their function. The signals from AhR-resveratrol
reaction might act as a mimic to the tumor-derived signals that
induce the suppressive function of MDSCs. Further studies are
needed to clarify this hypothesis.
Resveratrol has been shown to possess chemopreventive
activities such as suppression of tumor cell proliferation, induction
of tumor cell apoptosis, and enhancement of chemosensitization of
tumor cells [21,22,24,25]. It is known that resveratrol can directly
induce cell-cycle disruption and apoptosis in chemoresistant B16
melanoma that leads to tumor regresson; meanwhile, resveratrol
makes melanomas more susceptible to the chemotherapeutic drugs
[24,25]. Our results showed: (1) resveratrol significantly enhanced
the expression of FoxO1 gene of melanoma (Fig. 9A-9C). (2)
resveratrol dramatically increased the susceptibility of melanoma
to LAK cytotoxicity (Fig. 9D). It is known that FoxO1 controls the
tumor growth; the expression of FoxO1 inhibits the tumor growth
and triggers the ultimate death of tumor [31,32]. We propose that
the above two effects of resveratrol might compensate and
overcome the suppression of MDSC on the tumor infiltrating T
lymphocytes so as to promote anti-tumor immunity.
The response to immunotherapy with HDIL-2 in patients with
metastatic RCC and melanoma is about 15% to 23%. The
immune suppression caused by the HDIL-2 treatment, such as
induction of Tregs, could be part of the reason why HDIL-2
remains less effective [1,2,3,4,5,37,38]. Our results indicate that
induction of MDSC is also an important factor in affecting the
results of the treatment. The functional status of immune
suppression of MDSC could be related to the responsiveness of
the therapy in patients. The clinical evidence is needed to further
elucidate such an issue. Resveratrol could be act in two beneficial
ways in HDIL-2 therapy by suppressing endothelial damage while
enhancing sensitivity of tumor killing. In our previous studies, we
have shown that melanoma cells and ECs can show differential
susceptibility to LAK lysis based on the expression of CD44
variant isoforms [27]. Therefore, resveratrol might induce the
differential expression of CD44 variants in melanoma cells, ECs,
LAK, Treg, and MDSCs that contributes to the differential role of
resveratrol and MDSC in EC protection and tumor killing.
Further studies are necessary to address the role of resveratrol in
modulating CD44 isoform expression.
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